GlassScriptPhysician profile
Marion Anna Protano
NPI 1972745875
$73,688.58
in general payments reported to CMS, 2019-2025
37 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $967 · 2021: $7,894 · 2022: $2,081 · 2023: $16K · 2024: $16K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Food and Beverage: $3,146 · Education: $61.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,366.35 |
| Food and Beverage | $3,146.11 |
| Education | $61.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $66,298.35 | 2021-2025 | Capsocam Colon |
| Abbvie INC. | $2,009.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $851.99 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $635.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $476.57 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $315.60 | 2019-2024 | Livdelzi |
| Celgene Corporation | $248.00 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $243.62 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $221.58 | 2019-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $203.34 | 2020-2024 | Linzess |
| Medtronic, INC. | $190.63 | 2024-2025 | Interstim |
| Allergan, INC. | $186.05 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $179.40 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $159.78 | 2019-2024 | |
| Ardelyx, INC. | $157.73 | 2023-2025 | Ibsrela |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Anna Protano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.